First Manhattan
ENTA icon

First Manhattan’s Enanta Pharmaceuticals ENTA Stock Holding History

First Manhattan’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-263,375
Closed -$10.7M – 1459
2023
Q1 		$10.7M Buy
263,375
+19,657
+8% +$939K 0.04% 133
2022
Q4 		$11.3M Hold
243,718
– – 0.04% 138
2022
Q3 		$12.6M Buy
243,718
+15,911
+7% +$930K 0.05% 123
2022
Q2 		$10.8M Sell
227,807
-561,504
-71% -$30.5M 0.04% 148
2022
Q1 		$56.2M Sell
789,311
-180,425
-19% -$11.7M 0.18% 60
2021
Q4 		$72.5M Hold
969,736
– – 0.24% 54
2021
Q3 		$55.1M Buy
969,736
+936,536
+2,821% +$46.3M 0.2% 60
2021
Q2 		$1.46M Buy
+33,200
New +$1.63M 0.01% 378
2021
Q1 		– Sell
-237,679
Closed -$10M – 1486
2020
Q4 		$10M Sell
237,679
-137,206
-37% -$6.04M 0.05% 158
2020
Q3 		$17.2M Sell
374,885
-19,312
-5% -$936K 0.09% 106
2020
Q2 		$19.8M Sell
394,197
-18,000
-4% -$931K 0.11% 94
2020
Q1 		$21.2M Sell
412,197
-134,134
-25% -$7.15M 0.14% 85
2019
Q4 		$33.8M Buy
546,331
+37,701
+7% +$2.34M 0.17% 81
2019
Q3 		$30.6M Sell
508,630
-109,141
-18% -$8.11M 0.17% 86
2019
Q2 		$52.1M Sell
617,771
-47,163
-7% -$4.24M 0.29% 59
2019
Q1 		$63.5M Sell
664,934
-14,800
-2% -$1.33M 0.37% 49
2018
Q4 		$48.1M Sell
679,734
-18,700
-3% -$1.43M 0.3% 55
2018
Q3 		$59.7M Buy
698,434
+129,026
+23% +$12.9M 0.32% 53
2018
Q2 		$66M Sell
569,408
-302,367
-35% -$30.2M 0.38% 48
2018
Q1 		$70.5M Sell
871,775
-212,425
-20% -$16.3M 0.4% 43
2017
Q4 		$63.6M Buy
1,084,200
+137,100
+14% +$6.87M 0.35% 55
2017
Q3 		$44.3M Buy
947,100
+12,400
+1% +$498K 0.25% 74
2017
Q2 		$33.6M Buy
934,700
+56,200
+6% +$1.8M 0.2% 94
2017
Q1 		$27.1M Buy
878,500
+394,000
+81% +$12.3M 0.16% 104
2016
Q4 		$16.2M Buy
484,500
+311,200
+180% +$8.92M 0.1% 135
2016
Q3 		$4.61M Buy
+173,300
New +$4.02M 0.03% 251

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan's ENTA Position: Q2 2023 in Review

First Manhattan sold out of Enanta Pharmaceuticals (ENTA) in Q2 2023, closing a stake of 263,375 shares — an estimated $10.7M sold.

First Manhattan first reported a position in ENTA in Q3 2016 and held it in 26 quarters. The position peaked at $72.5M in Q4 2021. 133 funds tracked by Wall St. Rank hold ENTA as of Q2 2023.

  • First Manhattan reported no remaining Enanta Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • First Manhattan sold 263,375 Enanta Pharmaceuticals shares in Q2 2023, an estimated $10.7M.
  • First Manhattan first reported a position in Enanta Pharmaceuticals in Q3 2016 and held it in 26 quarters.
  • First Manhattan's Enanta Pharmaceuticals position peaked at $72.5M in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2023.

Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.